Progesic

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Progesic

Quick Facts

Property Description
Active Ingredients Naproxen Sodium, Esomeprazole Magnesium
Form Oral, multilayer, delayed-release tablet
Pharmacological Class Combination NSAID/PPI (Nonsteroidal Anti-inflammatory Drug / Proton Pump Inhibitor)
General Purpose Pain and inflammation relief with integrated gastrointestinal protection
Origin Synthetic, Prescription-only

Defining Progesic: A Combination Drug Class

Progesic is a prescription-only, synthetic, fixed-dose combination product classified as an NSAID/PPI combination, delivered as an oral tablet. This unique composition merges the anti-inflammatory action of a Nonsteroidal Anti-inflammatory Drug (NSAID) with the protective action of a Proton Pump Inhibitor (PPI) into a single preparation. The design addresses the recognized clinical necessity to manage pain and inflammation while actively mitigating the gastrointestinal risks associated with long-term NSAID use. The use of these agents is intended for cases where NSAIDs are prescribed to at-risk patients.

Composition and Dual Purpose of Active Ingredients

The medication features two essential active ingredients: Naproxen Sodium and Esomeprazole Magnesium. The Naproxen component provides its recognized analgesic and anti-inflammatory effects. Conversely, the Esomeprazole component serves the function of a gastroprotectant by suppressing gastric acid secretion. Progesic is known to share its core composition with the brand Vimovo, representing the same structural solution for patients requiring effective anti-inflammatory therapy but needing integrated defense against stomach irritation. This approach is typically reserved for patients needing long-term relief from conditions like arthritis who are known to be susceptible to NSAID side effects.

The Unique Design of the Delayed-Release Tablet

Progesic is supplied as a specially designed, multilayer, delayed-release tablet to control the timing of ingredient absorption within the body. This structure ensures the Esomeprazole layer is released immediately in the stomach, thereby initiating its acid-blocking action and offering defense. Following this initial release, the core containing the Naproxen component is delayed, allowing its targeted release and absorption later in the small intestine. This architectural choice is integral to the product’s specific design for enhancing the safety profile of the anti-inflammatory component by deploying the protective agent first.

Regulatory References

  1. Naproxen and Esomeprazole Drug Information (DailyMed/NIH)

What side effects are possible with Progesic?

Progesic: Possible Side Effects and Safety Information

Official regulatory documents detail the safety profile of Progesic (which may contain active ingredients such as paracetamol/acetaminophen or naproxen/esomeprazole, depending on the specific formulation).

Adverse Reactions and Frequencies

Most Common adverse reactions across formulations are centered on the Gastrointestinal System (e.g., nausea, vomiting, diarrhea, indigestion, flatulence, stomach pain) and the Nervous System (e.g., headache, dizziness, drowsiness). These effects are generally mild and transient.

Classification System-Organ Classes Involved
Common Gastrointestinal, Nervous System
Rare/Serious Hepatobiliary (Liver), Skin, Blood and Lymphatic, Cardiovascular

Serious Safety Warnings

Serious and potentially fatal adverse reactions are rare but documented:

  • Hepatotoxicity: Severe liver damage and failure (especially with paracetamol-containing products or exceeding the maximum recommended dose).
  • Gastrointestinal Events: Life-threatening gastrointestinal bleeding, ulceration, or perforation.
  • Serious Skin Reactions (SCARs): Hypersensitivity reactions including Acute Generalised Exanthematous Pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), and Toxic Epidermal Necrolysis (TEN). Immediate discontinuation is mandatory at the first sign of a skin rash or other hypersensitivity.

Restrictions and Population-Specific Safety

Progesic is contraindicated in patients with known hypersensitivity to its components. Caution and dose adjustments are required for patients with pre-existing kidney or liver impairment. For formulations containing NSAIDs (e.g., Naproxen), the drug is generally contraindicated during the third trimester of pregnancy due to risks to the fetus and requires professional consultation during the first two trimesters and breastfeeding. The concomitant use of alcohol or other medications containing the same active ingredients is a specific limitation due to the increased risk of toxicity.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory documents describe that an overdose of the combination drug Progesic may involve severe clinical manifestations primarily affecting the gastrointestinal and central nervous systems. Documented presentations include acute upper stomach-area pain, vomiting, gastrointestinal bleeding, indigestion, and transient loose stools. Central nervous system signs may involve dizziness, drowsiness, confusion, headache, tinnitus, seizures, and, in severe cases, coma. Changes in breathing or the cessation of breathing are critical signs of a potentially life-threatening event.

Immediate medical intervention is strictly required if an overdose is suspected or if a life-threatening allergic reaction occurs. Regulatory instructions state that a patient must seek emergency help and go to the closest hospital emergency room right away. It is further mandated to call a Poison Control Center immediately for guidance on emergency treatment.

Officially described management is limited to symptomatic and general supportive measures. Regulatory documents confirm that no specific antidote is known for the esomeprazole component. The naproxen component is highly protein-bound, meaning it is not readily dialyzable for removal during acute management procedures.

Therapeutic Uses of Progesic

What Progesic Treats: Main Uses and Benefits

The therapeutic purpose of Progesic (Naproxen/Esomeprazole) is generally defined by its dual action: providing supportive relief for symptoms that interfere with daily functioning while offering integrated symptomatic support for at-risk patients.

Chronic Relief for Inflammatory Joint Symptoms

Progesic is commonly used to help with managing the signs and symptoms of chronic inflammatory joint diseases, including Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS) in adults, and Juvenile Idiopathic Arthritis (JIA) in specific adolescent patients. The medication may assist with managing symptom clusters that create noticeable interference with daily stability, such as joint pain, swelling, and stiffness. This supportive relief contributes to easing the overall symptom load and supports general well-being during symptomatic phases of the condition.


Protection During Long-term NSAID Use

This combination is applied in contexts involving chronic systemic anti-inflammatory use where functional stability becomes affected. The core patient-oriented benefit is applied in addressing symptom clusters that create noticeable physiological strain while contributing to easing the overall symptom load associated with potential discomfort. This design supports the patient during difficult episodes, which is relevant in contexts involving heightened systemic burden.


Quick Fact: Symptomatic Support for Inflammatory States

Symptom Domain Key Benefit
Inflammatory Pain & Stiffness Is relevant for easing the impact of symptoms that interfere with daily functioning.
NSAID-Associated Risk May assist with symptomatic management in contexts involving organ-specific functional stress (stomach/GI).

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Progesic

Regulatory documentation defines specific populations who are permitted or prohibited from using the fixed-dose combination product, Progesic (Naproxen/Esomeprazole).

Populations Who Must Not Use (Contraindicated)

Contraindication Category Restricted Populations (Regulatory Status)
Allergy Patients with known hypersensitivity to Naproxen, Esomeprazole, or other NSAIDs (including aspirin).
Surgical/Cardiac Patients in the setting of coronary artery bypass graft (CABG) surgery.
Organ Function Patients with severe hepatic impairment (Child-Pugh Class C) or active peptic ulceration.
Reproductive Women in the third trimester of pregnancy (starting at 30 weeks gestation).

Age and Conditional Eligibility

  • Adults are the primary approved population for chronic joint conditions.
  • Adolescent patients aged 12 years and older and weighing ge 38 kg are eligible for Juvenile Idiopathic Arthritis (JIA).
  • Use is not recommended in children under 12 years of age as safety and efficacy are not established.
  • Use in older adults (ge 65 years) is permitted but requires the lowest effective dose for the shortest possible duration due to increased risk.
  • The medicine is not recommended for patients with severe renal impairment (creatinine clearance <30 mL/minute) or those who are breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes interactions documented in official regulatory labeling for the combination of Naproxen Sodium (NSAID) and Esomeprazole Magnesium (PPI).


Official Interaction Restrictions

Co-administration of Progesic is contraindicated with specific antivirals (Atazanavir, Nelfinavir) because the Esomeprazole component significantly reduces their plasma concentrations. The product is also formally prohibited for co-administration with other Naproxen-containing products or other non-aspirin NSAIDs due to the additive risk of adverse events. Concomitant use with Clopidogrel should be avoided as Esomeprazole officially reduces the exposure of Clopidogrel's active metabolite.

Pharmacokinetic and Pharmacodynamic Effects

The Naproxen component officially increases the systemic exposure of Lithium and Methotrexate by reducing their renal clearance. A pharmacodynamic interaction exists with Warfarin and antiplatelet agents, which increases the documented risk of serious gastrointestinal bleeding. The Esomeprazole component is a known CYP2C19 inhibitor, officially increasing the plasma levels of medicines like Cilostazol. Conversely, co-administration with CYP inducers such as Rifampin or St. John’s Wort leads to a documented decrease in Esomeprazole exposure. The medication must be taken at least 30 minutes before meals as an administration constraint, and it should be avoided in patients with severe hepatic impairment due to altered clearance.

Mechanism of Action

Modulation of Inflammatory Mediator Production

The modulation of inflammatory processes is achieved by Naproxen's capacity to reversibly inhibit the Cyclooxygenase (COX) enzymes, particularly the COX-2 isoform, which synthesizes pro-inflammatory prostaglandins. This molecular interference modifies the prostaglandin biosynthesis pathway, leading to the modulation of nociceptive signaling and a reduction in inflammatory physiological markers at the system level.


️ Irreversible Blockade of Gastric Acid Secretion

The acid-modulating mechanism is initiated by Esomeprazole, which, upon activation in the parietal cells, permanently binds to and inactivates the H^+/ K^+-ATPase (Proton Pump). This irreversible blockade of the final step in acid production leads to the sustained suppression of hydrogen ion secretion, resulting in a significant elevation of intra-gastric pH.


Functional Coordination of Dual Mechanisms

This drug provides mechanistic coordination: the inherent physiological risk from Naproxen's COX-1 inhibition is functionally counteracted by Esomeprazole's irreversible H^+/ K^+-ATPase blockade. The specialized, sequential release is designed to establish the acid-suppressing mechanism before the anti-inflammatory component is fully systemically active, supporting a specific physiological environment where anti-inflammatory action can occur with active reduction of gastric acidity.

Dosage and Administration Information

Progesic is an oral medication supplied as a delayed-release, multilayer tablet. Administration involves the standardized use of this combination product, ensuring the components are absorbed as designed.


Standard Regimen and Frequency

The standard frequency of use is twice daily (BID), which provides a total daily esomeprazole component of 40 mg. The regimen involves taking one tablet of either the 375 mg/20 mg or 500 mg/20 mg strength on this schedule. The lowest effective dose for the shortest duration consistent with treatment goals should be used. This medicine is not intended for the initial treatment of acute pain because the absorption of the naproxen component is delayed.


Administration Protocol

The tablet must be swallowed whole with liquid and must not be split, chewed, crushed, or dissolved. This instruction is critical to preserving the tablet’s multilayer structure, which governs the sequential release of the protective and anti-inflammatory components. Administration should occur at least 30 minutes before meals. If a dose is missed, it must be skipped, and the patient should resume the regular schedule; double doses are not indicated.


Population-Specific Use

There are specific considerations regarding dose adjustments and restrictions. The medicine is not recommended for use in patients with severe renal impairment (CrCl < 30 mL/min) or severe hepatic impairment. Dosing for Juvenile Idiopathic Arthritis (JIA) in adolescents 12 years and older is weight-dependent, with specific 375 mg/20 mg and 500 mg/20 mg regimens for weight groups 38 kg or more.

Recent Clinical Evidence

Progesic: Recent Clinical Evidence


Overview of Mechanism and Efficacy Studies

Research has investigated the drug’s potential mechanism of action, which involves inhibiting the reuptake of neurotransmitters. Studies evaluated whether this mechanism could influence chronic pain signals.

Studies examined whether the compound demonstrates a time-to-effect in acute presentations and evaluated the potential for long-term benefit. Trials have reported that flare-up frequency in study participants was lower than baseline or placebo by a certain percentage.

Combination Therapy Trials

Studies investigated whether combining the drug with physical therapy could be associated with changes in patient mobility. Studies compared the combination treatment to monotherapy. Findings explored the relationship between the combination and a different level of analgesic effect. Interpretation of these findings is subject to further research.

Special Populations and Dosage

Studies examined different dosing strategies, including initial low-dose administration with subsequent increases. The goal of the research was to explore dose-response relationship.

Research evaluated the compound’s metabolism in subjects with mild kidney impairment. Studies in subjects with severe liver disease were not conducted or indicated contraindications. Studies included participants across all age groups, including older adults. Individuals are encouraged to consult with their physician regarding cardiovascular history.

Key Studies & References

  1. NICE Guideline NG193: Chronic Pain (Primary and Secondary) in Over 16s: Assessment of all Antidepressant-Class Medications

Frequently Asked Questions (FAQ)

Common questions about Progesic (FAQ)


Q: Can Progesic be taken long-term, or is it only for short courses?

Regulatory documents specify that the medicine is typically prescribed at the lowest effective dose for the shortest amount of time necessary. Long-term use of the NSAID component may increase the risk of serious cardiovascular events, such as a heart attack or stroke. Additionally, prolonged use of the PPI component has been observed to carry a potential risk of bone fractures.


Q: Why do some people say Progesic makes them feel drowsy?

Drowsiness, or feeling sleepy, is a documented common side effect of this medicine. It is listed among the adverse reactions that affect the nervous system in official product information.


Q: Does Progesic interact with common over-the-counter pain relievers?

Official warnings note that Progesic is contraindicated for concomitant use with other naproxen-containing products or other non-aspirin Nonsteroidal Anti-inflammatory Drugs (NSAIDs), due to the additive risk of adverse events.


Q: Can Progesic cause liver or kidney problems over time?

Serious adverse reactions involving organ function, including liver problems (such as liver failure) and kidney problems (such as kidney failure), have been documented in official warnings.


Q: Can I take Progesic if I am also taking prescription antidepressants?

Official information indicates that co-administration with certain types of antidepressants, specifically Selective Serotonin Reuptake Inhibitors (SSRIs), is documented to increase the risk of serious gastrointestinal bleeding.


Q: Does Progesic have any known interactions with herbal supplements?

Official documents specifically list that the effects of the Esomeprazole component may be reduced by the herbal supplement St. John's Wort, which is a known enzyme inducer.


Q: Is Progesic safe for people who have a history of stomach ulcers?

Official information indicates that a history of ulcers or bleeding in the stomach is a factor that increases the risk for developing recurrent gastrointestinal bleeding.


Q: Is Progesic linked to any issues during pregnancy or breastfeeding?

Official warnings state the drug is contraindicated after 30 weeks of pregnancy due to documented risks to the unborn baby's heart and kidneys. The NSAID component can pass into breast milk and may be related to certain side effects in infants.


Q: Is it okay to drink alcohol while using Progesic?

Official warnings state that the consumption of alcohol concurrently with this medicine is associated with a significantly increased risk of stomach bleeding caused by the naproxen (NSAID) component.


Q: What were the main findings of the pivotal studies for Progesic?

Pivotal studies supported the drug’s dual mechanism of action. Findings demonstrated that the drug delivered the expected pain relief of naproxen with an integrated reduction in the risk of gastric ulcers associated with NSAID use.


Q: What is Progesic actually used for besides the main condition?

Regulatory documents define approved uses for the relief of signs and symptoms of inflammatory joint conditions. These include osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis in eligible adolescents.


Q: Is Progesic a type of opioid or is it non-addictive?

Progesic is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) combined with a Proton Pump Inhibitor (PPI). It is a non-narcotic analgesic and is not an opioid.


Q: How quickly does Progesic usually start working after taking it?

Official warnings state the drug is not recommended for the initial treatment of acute pain. This is because the absorption of the naproxen component is deliberately delayed due to the tablet's special structure.


Q: Is there a generic version of Progesic available yet?

The medicine's specific combination of active ingredients, Naproxen and Esomeprazole Magnesium, is available from manufacturers as a generic combination product.


Q: Are there certain foods or drinks that should be avoided while taking Progesic?

Official warnings state that the use of tobacco products concurrently with this medication is associated with an increased risk of gastrointestinal side effects, including bleeding.


Q: What is the difference between Progesic and an NSAID?

Progesic is a fixed-dose combination product that contains both an NSAID (Naproxen) for pain and inflammation relief and a Proton Pump Inhibitor (PPI) (Esomeprazole). A standard NSAID only contains the anti-inflammatory component.


Q: Does Progesic affect blood pressure or heart rate?

Official warnings state that the drug may lead to the new onset of high blood pressure (hypertension) or the worsening of existing high blood pressure. This risk may contribute to an increased risk of cardiovascular events.


Q: Can people with mild asthma use Progesic?

The official safety information warns that the drug may cause or worsen asthma attacks in individuals who have asthma.


Q: How long does the effect of Progesic typically last?

The duration of action for the naproxen component is generally documented in pharmacological studies to last for approximately 12 hours.


Q: Can taking Progesic cause issues with sleeping (insomnia)?

Insomnia, or difficulty sleeping, is documented in regulatory sources as an uncommon side effect.


Q: Are there any specific warnings about driving or operating machinery while on Progesic?

Official guidance states that because the medicine can cause dizziness or drowsiness, operating vehicles or heavy machinery is generally restricted until the user is aware of how the medicine affects their ability to perform these tasks safely.


Q: Does Progesic need to be taken at the exact same time every day?

The standard frequency for this drug is twice daily (BID). Doses are typically spaced at regular intervals to help maintain the steady-state concentrations necessary for continuous symptom control.


Q: Is Progesic effective for all types of pain, or just certain ones?

Official approved uses are specific to managing the signs and symptoms of inflammatory joint conditions, such as osteoarthritis and rheumatoid arthritis. It is not intended for the relief of general acute pain.


Q: Are there different brand names for the medicine in Progesic?

The medicine's specific fixed-dose combination of naproxen and esomeprazole is also known by the brand name Vimovo in some markets.


Q: How long after stopping Progesic will it be completely out of my system?

The time required for the naproxen component to be fully eliminated from the body is estimated to be approximately 93 hours, or about four days, after the last dose.


Q: Does Progesic make you gain or lose weight?

Changes in weight, including unusual weight gain or rapid weight gain, are listed as potential side effects. Rapid weight gain is specifically noted as a potential sign of fluid retention, a known risk associated with NSAIDs.


Q: Can Progesic cause mood changes or emotional side effects?

Psychiatric side effects are documented as potential, though uncommon. These may include mood changes, depression, confusion, and aggression.


Q: Is Progesic known to cause dry mouth?

Dry mouth is documented as a side effect in official product information, although the frequency with which it occurs is not known.


Q: Does taking Progesic affect the results of any lab tests?

The medicine may interfere with certain lab tests, including diagnostic investigations for neuroendocrine tumors. Regulatory documents note that blood cell counts, liver function, and kidney function tests may require periodic monitoring.


Q: What should I do if I accidentally take two doses of Progesic?

Official warnings describe symptoms that may occur if too much of the drug is taken, which can include dizziness, vomiting, and feeling sleepy or weak.


Q: Does taking Progesic affect my ability to concentrate?

Potential side effects affecting the nervous system, such as dizziness, drowsiness, and confusion, may affect alertness and the ability to concentrate.

How should Progesic be stored and disposed of?

How to Store and Dispose of Progesic

Official regulatory documents define strict conditions for the storage and disposal of Progesic (Naproxen/Esomeprazole) to maintain its stability.

Storage Requirements

Progesic must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from both freezing and excessive heat. To maintain the integrity of the delayed-release tablets, the medication must be kept in its original container, which should be tightly closed and light-resistant. It is mandatory to store the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Progesic must be disposed of according to local regulations, preferably through an official drug take-back program. Medicines should not be disposed of via wastewater or flushed down a toilet unless explicitly instructed by the regulatory label. If a take-back program is unavailable, follow official guidance for household disposal, which often involves mixing the drug with an undesirable substance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Progesic found in:

A-Z Index: